載入中
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
前收盤價
US$4.29
−US$0.19 · -4.24%
盤前
US$4.35
+US$0.06 · +1.40%
10月8日 上午4:56 ET
盤中時間採用ET。市場資料可能有所延遲。
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
日內區間
目前US$4.29
52週區間
目前US$4.29
盤中時間採用ET。市場資料可能有所延遲。
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
日內區間
目前US$4.29
52週區間
目前US$4.29
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1408.3萬 USD | 617.1萬 USD | 1814.1萬 USD | 3901.9萬 USD | 1098.8萬 USD |
| 銷貨成本 | 36.3萬 USD | — | — | — | — |
| 毛利 | 1372萬 USD | 617.1萬 USD | 1814.1萬 USD | 3901.9萬 USD | 1098.8萬 USD |
| 研究與開發 | 2524.1萬 USD | 5403.7萬 USD | 7370萬 USD | 8440.8萬 USD | 6550.2萬 USD |
| 銷售、一般及管理費用 | 1589.3萬 USD | 2210.8萬 USD | 2247.5萬 USD | 1783.4萬 USD | 1713.6萬 USD |
| 營業費用 | 4077.1萬 USD | 8249萬 USD | 9624.4萬 USD | 1.04億 USD | 8451萬 USD |
| 利息收入 | 406.8萬 USD | 658.5萬 USD | 568.8萬 USD | 219.2萬 USD | 12.7萬 USD |
| 利息支出 | 9.7萬 USD | 13.7萬 USD | 45.9萬 USD | 172.6萬 USD | 285.7萬 USD |
| 折舊和攤銷 | 36.3萬 USD | 138萬 USD | 140.4萬 USD | 142.7萬 USD | 175.3萬 USD |
| 營業利益 | −2705.1萬 USD | −7631.9萬 USD | −7810.3萬 USD | −6545.6萬 USD | −7352.2萬 USD |
| 淨利 | −3350.1萬 USD | −6992萬 USD | −7284.9萬 USD | −6945.6萬 USD | −7624.7萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.50
上漲空間 98.14%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2010年11月4日 | 1:5 | — | — |
已生效 2010年11月4日
1:5
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2557.55萬0.00%2.3兆 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM1843.21萬0.02%785.63億 USD0.19%US$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI1310.58萬0.13%100.75億 USD0.35%US$150.23-0.44%
Vanguard Extended Market ETFVXF931.49萬0.01%954億 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO681.99萬0.05%142.49億 USD0.24%US$355.37-1.43%
iShares Biotechnology ETFIBB540.75萬0.05%104.01億 USD0.44%US$203.34+0.12%
Vanguard Russell 2000 ETFVTWO469.08萬0.03%180億 USD0.06%US$112.21-1.26%
Janus Henderson Small Cap Growth Alpha ETFJSML404.02萬1.12%3.61億 USD0.30%US$86.5304-1.55%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOJanus Henderson Small Cap Growth Alpha ETFJSMLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
